"Making Strides against Breast Cancer"
Joanne Inamdar found her cancer while watching late night television. After finding out that it was triple-negative breast cancer, Inamdar enrolled in a clinical trial at The Mount Sinai Hospital. “Most breast cancers are very sensitive to hormonal treatment, but triple negative means they’re growing via other pathways, which on an individual basis we really can’t define,” said Elisa Port, MD, co-director of the Dubin Breast Center at The Mount Sinai Hospital. “The goal is to create individual models personalized for individual patients,” said Hanna Irie, MD, PhD, an assistant professor of medical oncology at the Icahn School of Medicine at Mount Sinai. Dr. Irie is a co-principle investigator on the xenograft trial Inamdar joined. “Every patient that has benefited from the treatment options we have today has benefited because someone was altruistic previously and participated in these trials,” Dr. Port said. Learn more: part 1, part 2.
Mount Sinai’s Dubin Breast Center Annual Benefit Raises Over $2.5 Million
Feb 08, 2022 View All Press Releases
Future Breast Imaging and Biopsy Are Not Eliminated After Mastectomy
Oct 09, 2018 View All Press Releases